232 related articles for article (PubMed ID: 17896784)
1. Positron emission tomography imaging in nonsmall-cell lung cancer.
Erasmus JJ; Macapinlac HA; Swisher SG
Cancer; 2007 Nov; 110(10):2155-68. PubMed ID: 17896784
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
Truong MT; Viswanathan C; Erasmus JJ
J Thorac Imaging; 2011 May; 26(2):132-46. PubMed ID: 21508735
[TBL] [Abstract][Full Text] [Related]
3. Value of FDG PET in the management of NSCLC.
Ukena D; Hellwig D
Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
[TBL] [Abstract][Full Text] [Related]
4. Prognosis and reevaluation of lung cancer by positron emission tomography imaging.
Erasmus JJ; Rohren E; Swisher SG
Proc Am Thorac Soc; 2009 Apr; 6(2):171-9. PubMed ID: 19349485
[TBL] [Abstract][Full Text] [Related]
5. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
6. Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).
Miele E; Spinelli GP; Tomao F; Zullo A; De Marinis F; Pasciuti G; Rossi L; Zoratto F; Tomao S
J Exp Clin Cancer Res; 2008 Oct; 27(1):52. PubMed ID: 18928537
[TBL] [Abstract][Full Text] [Related]
7. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients.
Kim YK; Lee KS; Kim BT; Choi JY; Kim H; Kwon OJ; Shim YM; Yi CA; Kim HY; Chung MJ
Cancer; 2007 Mar; 109(6):1068-77. PubMed ID: 17311309
[TBL] [Abstract][Full Text] [Related]
8. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
[TBL] [Abstract][Full Text] [Related]
9. [Detection of unexpected extrathoracic metastases in preoperative staging of non-small-cell bronchial carcinoma (NSCLC) with positron emission tomography (PET)].
Schmid RA; Hillinger S; Bruchhaus H; Steinert HC; von Schulthess GK; Largiadèr F; Weder W
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1264-7. PubMed ID: 9931854
[TBL] [Abstract][Full Text] [Related]
10. [Current status of 18F-FDG PET in predicting outcome of cancer therapy].
Gong HY; Yu JM
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):577-80. PubMed ID: 16429617
[No Abstract] [Full Text] [Related]
11. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
[TBL] [Abstract][Full Text] [Related]
12. Non-small cell lung cancer: FDG-PET imaging.
Erasmus JJ; McAdams HP; Patz EF
J Thorac Imaging; 1999 Oct; 14(4):247-56. PubMed ID: 10524805
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
[TBL] [Abstract][Full Text] [Related]
14. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology.
Vansteenkiste JF; Stroobants SG
Eur Respir J; 2001 Apr; 17(4):802-20. PubMed ID: 11401078
[TBL] [Abstract][Full Text] [Related]
15. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
Guan Y; He S; Dong J
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls.
Vansteenkiste JF
Lung Cancer; 2005 Feb; 47(2):151-3. PubMed ID: 15639713
[No Abstract] [Full Text] [Related]
17. [18F]Fluorodeoxyglucose PET in Thoracic Malignancies.
Vilstrup MH; Torigian DA
PET Clin; 2014 Oct; 9(4):391-420, v. PubMed ID: 26050944
[TBL] [Abstract][Full Text] [Related]
18. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
[TBL] [Abstract][Full Text] [Related]
19. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review.
Mac Manus M; Hicks RJ
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1298-306. PubMed ID: 19028270
[No Abstract] [Full Text] [Related]
20. PET-CT in the staging and treatment of non-small-cell lung cancer.
Ibeas P; Cantos B; Gasent JM; Rodríguez B; Provencio M
Clin Transl Oncol; 2011 Jun; 13(6):368-77. PubMed ID: 21680297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
